EBV-positive DLBCL patients respond poorly and show variations to standard R-CHOP regimen with regard to ethnic background, CD30 expression, geographical distribution and oncogenic signaling activation. This evidence concerns the gene TNFRSF8 and diffuse large B-cell lymphoma.